Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Response to the correspondence: "Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma".

Bateman ED., Khan AH., Xu Y., Guyot P., Chao J., Kamat S., Rowe P., Burnett H., Msihid J., Weinreich D., Pavord ID.

More information

DOI

10.1016/j.rmed.2020.106088

Type

Journal article

Publication Date

01/01/2022

Volume

191

Addresses

Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Electronic address: eric.bateman@uct.ac.za.

Keywords

Humans, Asthma, Biological Products, Antibodies, Monoclonal, Humanized